Beta-lactamases: clinical impact and epidemiology

Published on December 31, 2009 Updated on November 30, 2015   38 min

Other Talks in the Series: Antibiotic Resistance

0:00
My name is Sebastian Amyes, and I'm professor of antimicrobial chemotherapy at the University of Edinburgh in Scotland in the north of the United Kingdom. I and my colleagues have spent much of our careers looking at beta-lactamases, both their structure and function, and putting this into context with clinical impact and epidemiology. In this presentation I shall talk about the impact of beta-lactamases and outline some of the most important beta-lactamases that we're having to deal with in the clinical situation today.
0:33
Most of the beta-lactamases I'm going to talk about are in Gram-negative bacteria. There are, of course, beta-lactamases in Gram-positive bacteria and they have caused problems clinically, but largely they are overcome by new drugs such as methicillin and the newer cephalosporins. There are more than 2,000 beta-lactamases reported since their first discovery by Abraham and Chain in 1940. And many of these are of clinical importance. The ones that I'm particularly going to talk about are those that cause problems at the moment, those that confer resistance to the cephalosporins. The transferable class C beta-lactamases and what we know as extended-spectrum beta-lactamases. Also, I'm going to talk about those that confer resistance to the carbapenems. The transferable class B and transferable class D beta-lactamases, but we would discuss these in more detail later on.
Hide

Beta-lactamases: clinical impact and epidemiology

Embed in course/own notes